RAF1 and melanoma: There is an ongoing clinical trial evaluating a pan-RAF inhibitor in combination with ERK or MEK inhibitors in KRAS-mutant non-small cell lung cancer and NRAS-mutant melanoma which will hopefully provide insights about RAF-ERK vs RAF-MEK inhibitory combinations (NCT02974725) (Ozkan-Dagliyan et al., 2020).